In a nutshell This study investigated the risk of developing a range of thyroid disorders in both childhood and adult-treated female survivors of Hodgkin lymphoma (HL). The data showed that the risk of developing thyroid disorders increased significantly over time in both childhood and adult-treated survivors of HL. Some background Hodgkin lymphoma...
Read More
In a nutshell This study compared the health-related quality of life (HR-QoL) outcomes between pembrolizumab (Keytruda) and brentuximab vedotin (BV; Adcetris) in patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that the pembrolizumab improved the HR-QoL outcomes compared to BV in these patients. Some...
Read More
In a nutshell This study investigated the potential benefits of radiotherapy (RT) for the treatment of patients with advanced-stage Hodgkin lymphoma (HL) who have achieved a complete metabolic response (CMR) after ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)-based chemotherapy. The data showed no significant difference in patient outcomes...
Read More
In a nutshell This study aimed to investigate the risk of infections in patients with blood cancers who were treated with new biological therapy drugs. This study concluded that a high proportion of these patients experienced severe infections. However, the infection risk was similar to that of chemotherapy. Some background...
Read More
In a nutshell This study aimed to evaluate brentuximab vedotin (BV; Adcedris) and bendamustine (Treanda) treatment in pediatric patients with relapsed/refractory (r/r) Hodgkin Lymphoma (HL). This study concluded that this treatment combination was safe and effective in these patients. Some background HL is a common cancer...
Read More
In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...
Read More
In a nutshell The authors compared the safety and effectiveness of 90Y-antiCD25 (yttrium 90 basiliximab; aTac) radioimmunotherapy (RAI), followed by BEAM (carmustine, etoposide, cytarabine, melphalan) and autologous stem cell transplantation (ASCT) for the treatment of patients with high-risk relapsed or refractory (r/r) classical Hodgkin...
Read More
In a nutshell This review looked at options to preserve future fertility for young people diagnosed with blood cancer. Some background For teens and young adults, blood and bone marrow cancers are one of the most common types of cancer. These include Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), and acute myeloid leukemia. Fortunately, blood...
Read More
In a nutshell This study evaluated the characteristics, treatment patterns, and outcomes of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (HL) after treatment with first-line therapy. Some background HL is a cancer of white blood cells. Most patients with HL respond to first-line chemotherapy regimens. However, up to...
Read More
In a nutshell This study evaluated treatment options and outcomes for older patients with classic Hodgkin lymphoma (HL). This study concluded that conventional chemotherapy regimens remain a standard of care for these patients. Some background Chemotherapy remains the standard first-line treatment for cHL. One of the most commonly used regimens...
Read More
In a nutshell This study looked at whether radiotherapy had an impact on the recurrence rate in patients with early-stage Hodgkin lymphoma (HL). It found that in patients with early-stage HL who responded fully to chemotherapy, the addition of radiotherapy reduced the risk of localized recurrence. Some background Early-stage...
Read More
In a nutshell This study looked at the 30-year risk of heart disease in patients with Hodgkin lymphoma (HL) treated with radiotherapy. It found that radiotherapy led to a small increase in the risk of death from heart disease or stroke in these patients. Some background HL is often treated with a combination of chemotherapy and...
Read More
